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6/j.bThe impact of National Institutes of Health consensus criteria (NCC) graft-versus-host disease (GVHD) on
survival has rarely been investigated in a large cohort of patients with GVHD presenting before and after
day 100 posttransplantation. We retrospectively investigated 775 patients who underwent allogeneic stem
cell transplantation and assessed the GVHD effects on survival by the time-dependent covariates in Cox pro-
portional hazards regression models. Using the NCC, the patients were classified into 4 groups: (1) noGVHD
(n5 251); (2) acuteGVHD (aGVHD) only (n5 199), including 26 patients with late aGVHD; (3) classic chronic
GVHD (cGVHD; n5 232); and (4) overlap syndrome (OS; n5 93). Multivariate analyses showed that classic
cGVHD(hazard ratio [HR], 0.46; 95%confidence interval [CI], 0.27-0.77) andOS (HR, 0.52; 95%CI, 0.28-0.96)
were associated with significantly decreased risk of relapse, whereas aGVHD only was not associated with re-
lapse rate (HR, 1.11; 95% CI, 0.76-1.63). All aGVHD events, including the period of aGVHD in patients who
developed cGVHD after aGVHD, also did not affect the risk of relapse (HR, 0.74; 95% CI, 0.49-1.12). All types
of GVHD were significantly associated with higher nonrelapse mortality in common. Finally, patients with
aGVHD only had significantly lower overall survival and disease-free survival compared with those without
GVHD, in contrast to favorable survival outcomes in patients with cGVHD without previous aGVHD. This
study demonstrates that NCC GVHD type is associated with different graft-versus-tumor effects. Further
studies are needed to investigate risk factors, pathogenesis, and biomarkers for each type of NCC GVHD.
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bmt.2012.01.010stem cell transplantation (SCT) [1-3]. Traditionally,
the diagnosis of GVHD has been based on the time
of onset, either less than or more than 100 days after
SCT [4]. However, advances in SCT practice, includ-
ing reduced-intensity conditioning (RIC) and donor
lymphocyte infusion (DLI), have altered the natural
history and presentation of both acute GVHD
(aGVHD) and chronic GVHD (cGVHD) and have
called previous definitions into question [1]. In this
context, the National Institutes of Health (NIH) con-
sensus criteria (NCC) for the diagnosis of cGVHD
emphasize the manifestations of GVHD instead of
the time of onset after SCT [1].
The new NCC criteria are based on expert opin-
ion, and studies for their validation are needed. In
a previous study, we determined the feasibility of the
NCC in patients with traditionally defined cGVHD
after SCT [5]. In addition, several studies have evalu-
ated the effect of NCC-defined GVHD subtype on
major outcomes [6-11]. These previous studies have
Biol Blood Marrow Transplant 18:1136-1143, 2012 1137GVT Effect of GVHD by NIH Criteriacommon points in evaluating the impact of each NCC
GVHD subtype, especially aGVHD or cGVHD, on
survival. First, they included only patients who
survived beyond 100 days after transplantation and
had GVHD presenting after day 100, and there were
no data on patients with NCC aGVHD or cGVHD
presenting before day 100. Second, most previous
studies could not evaluate the impact of GVHD on
survival compared with patients without GVHD,
because the onset of GVHD was used as the baseline,
precluding the need for time-dependent analyses. In
addition, few trials evaluated the presence or differ-
ence in graft-versus-tumor (GVT) effects of each
NCCGVHDsubtype in a cohort including all patients
throughout the course of SCT.
The aim of this study was to investigate whether
or not aGVHD or cGVHD by the NCC affects sur-
vival, especially on the rate of relapse and nonrelapse
mortality (NRM) in a cohort, including patients with
GVHD presenting before day 100 post-SCT and
those presenting after day 100 post-SCT. Thus, we
retrospectively reclassified historically defined GVHD
and compared the impact of NCC-classified aGVHD
and cGVHD on survival outcomes using time-
dependent Cox proportional hazards regressionmodels
[12,13].MATERIALS AND METHODS
Patient Selection
We examined 775 consecutive patients who under-
went allogeneic SCT from sibling and unrelated do-
nors for hematologic malignancies at the Catholic
Blood and Marrow Transplantation Center between
January 2002 and December 2008. The Institutional
Review Board of The Catholic University of Korea
approved the research protocol for data analysis. We
created a separate cohort comprising 747 patients, ex-
cluding recipients of second allogeneic SCT and/or
DLI, to investigate the impact of GVHD on overall
survival excluding the effect of postrelapse treatment.
Transplantation Procedures
Patients received either a myeloablative condition-
ing regimen (total body irradiation [TBI] and cyclo-
phosphamide; TBI and busulfan; TBI, cytarabine,
and melphalan; or busulfan and cyclophosphamide;
n 5 540) or RIC (fludarabine and busulfan with or
without TBI 400 cGy or fludarabine and melphalan;
n 5 235). Overall, 483 patients received bone marrow
(BM), and 247 received granulocyte colony-stimulating
factor–mobilized peripheral blood stem cells (PBSCs).
Forty-five patients received granulocyte colony-
stimulating factor–primed unmanipulated BM plus
CD341-enriched PBSCs to reduce the risk of graft
failure. HLA matching was based on serologic typingfor HLA-A, -B, and -C antigens and molecular typing
for HLA-DRB1 in 2002, and on molecular typing
for HLA-A, -B, -C, and -DRB1 from 2003 to 2008.
GVHD prophylaxis was based on a calcineurin inhib-
itor with a short course of methotrexate, with the cal-
cineurin inhibitor dose tapered gradually starting on
day 100 to 120 after SCT in the absence of aGVHD.
The other general transplantation procedures were
performed as described previously [14,15].
Diagnosis and Management of GVHD
The diagnosis of aGVHD or cGVHD was made
based on consensus criteria as described previously
[2,4]. Only aGVHD grade II to IV was considered
aGVHD for the purpose of this study. The primary
treatment for patients with aGVHD consisted mainly
of methylprednisolone (2 mg/kg) or an equivalent dose
of prednisone. The treatment of steroid-refractory
aGVHD was variable, as described previously [16].
The treatment of cGVHD also varied but followed
general guidelines as described previously [5]. In brief,
according to the Seattle criteria [2], limited types were
treated with topical immunosuppressants, and extensive
types were treated with calcineurin inhibitors along
with systemic steroids.
Reclassification of GVHD
All patients were reclassified by the NCC accord-
ing to history of aGVHD or cGVHD [1] into the fol-
lowing 4 groups regardless of time of onset: (1) no
GVHD, patients who experienced no GVHD or
only grade I aGVHD without cGVHD; (2) aGVHD
only, patients with only acute features of GVHDwith-
out cGVHD; (3) classic cGVHD, patients with
chronic features with or without previous aGVHD;
and (4) overlap syndrome (OS), patients with both
acute and chronic features simultaneously. According
to the onset pattern of chronic features, classic
cGVHD can be divided into 2 subtypes, de novo and
quiescent. OS comprises 3 subtypes of onset patterns:
(1) de novo, patients with no previous history of
GVHD; (2) quiescent, patients with a history of re-
solved acute or chronic features of GVHD; and (3)
progressive, patients with de novo aGVHD who later
developed chronic features with persistent former
acute features.
Statistical Analysis
The main purpose of this study was to evaluate the
differences in survival outcomes between aGVHD and
cGVHD occurring at any time after SCT.Major study
endpoints were overall survival, disease-free survival
(DFS), and cumulative incidences of relapse or NRM.
Kaplan-Meier curves were used to estimate the proba-
bility of overall survival and DFS, and cumulative inci-
dence was used to estimate the probability of relapse,
Table 1. Patient and Transplantation Characteristics
Parameter
All Patients
(n 5 775)
Only aGVHD
(n 5 199)
Classic cGVHD
(n 5 232) OS (n 5 93) P Valuea
Patient age, years, median (range) 36 (15-68) 33 (15-60) 37 (15-64) 38 (15-65) <.001
Patient sex, M/F, n (%) 426 (55)/349 (45) 108 (54)/91 (46) 127 (55)/105 (45) 60 (65)/33 (35) .236
Donor sex, M/F, n (%) 474 (61)/301 (39) 130 (65)/69 (35) 138 (60)/94 (40) 55 (59)/38 (41) .574
Donor–recipient sex match: female to male/other,
n (%)b
169 (22)/606 (78) 37 (19)/162 (81) 53 (23)/179 (77) 24 (26)/69 (74)
Diagnosis, n (%) .153
Myeloid 515 (67) 123 (62) 151 (66) 61 (66)
AML/CML/MDS 367 (47)/82 (11)/68 (9) 96 (48)/15 (8)/12 (6) 106 (46)/21 (9)/25 (11) 48 (52)/4 (4)/9 (10)
Lymphoid 260 (33) 76 (38) 81 (34) 32 (34)
ALL/PM 228 (29)/31 (4) 76 (38)/0 (0) 65 (28)/15 (6) 23 (25)/9 (10)
Pre-SCT disease status: standard/advanced, n (%)c 622 (80)/153 (20) 160 (80)/39 (20) 190 (82)/42 (18) 75 (81)/18 (19)
Donor type, n (%) .001
Sibling 492 (63) 106 (53) 167 (72) 59 (63)
Unrelated 283 (37) 93 (47) 65 (28) 34 (37)
WM/PM/MM, n (%) 152 (20)/100 (13)/31 (4) 43 (22)/37 (19)/13 (6) 41 (18)/19 (8)/5 (2) 19 (20)/10 (11)/5 (5)
ABO match/mismatch, n (%) 385 (50)/390 (50) 91 (46)/108 (54) 130 (56)/102 (44) 47 (51)/46 (50)
Graft source: BM/PBSC/BM + PBSC, n (%) 483 (62)/247 (32)/45 (6) 143 (72)/46 (23)/10 (5) 121 (52)/93 (40)/18 (8) 47 (51)/39 (42)/7 (7)
Conditioning: TBI-based/non–TBI-based, n (%) 583 (75)/192 (25) 146 (78)/53 (22) 181 (78)/51 (22) 69 (74)/24 (26)
Conditioning intensity: MAC/RIC, n (%) 540 (70)/235 (30) 165 (83)/34 (17) 141 (61)/91 (39) 58 (62)/35 (38) <.001
CD34+ cell dose ( 106/kg), median (range) 3.9 (0.3-49.0) 3.8 (0.3-34.4) 4.3 (0.3-30.0) 4.3 (1.2-33.7)
CD3+ cell dose ( 107/kg), median (range) 4.5 (0.04-109.70) 4.6 (0.14-68.41) 4.7 (0.04-109.70) 6.0 (0.20-78.16) <.001
GVHD prophylaxis: CS-based/FK506-based, n (%) 450 (58)/325 (42) 98 (49)/101 (51) 151 (65)/81 (35) 54 (58)/39 (42) .011
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CS, cyclosporine; MDS, myelodysplas-
tic syndrome; MM, mismatched; MAC, myeloablative conditioning; PM, plasma cell myeloma; PW, partially matched; WM, well matched.
aValues for categorical variables were analyzed using the c2 or Fisher exact test to compare the characteristics of the 3 GVHD subtypes. One-way anal-
ysis of variance was used to compare continuous variables.
bIncluding male to male (n 5 257), female to female (n 5 132), and male to female (n 5 217).
cAdvanced disease status at SCT includes AML or ALL beyond first remission, CML beyond first chronic phase, high-risk MDS (IPSS intermediate-2 or
higher), and PM with chemoresistance.
1138 Biol Blood Marrow Transplant 18:1136-1143, 2012B.-S. Cho et al.NRM, and eachNCCGVHDsubtype, treating nonre-
lapse death, relapse, and non-GVHD death as respec-
tive competing risks [12,13]. Values for categorical
variables were analyzed using the c2 or Fisher exact
test to compare the characteristics of 3 groups of
GVHD. One-way analysis of variance was used to
compare the continuous variables.
Potential factors affecting survival outcomes
were identified by multivariate analyses using Cox
proportional hazards regression models [12,13]. As
described previously [17], the proportionality assump-
tion was tested by adding a time-dependent covariate
for each factor (Figure S1). For factors violating the
proportionality assumption, models were constructed
dividing the posttransplantation course into 2 time
periods, using the maximized partial likelihood
method to find the most appropriate breaking point
(Table S1). A stepwise model selection approach was
used to identify all significant factors. The effects of
the 3 GVHD groups on survival outcomes were
assessed using time-dependent covariates in the final
multivariate model. To accommodate changes in
GVHD type after SCT (ie, aGVHD followed by
cGVHD), we undertook separate multivariate analyses
using the Cox proportional hazards regression models
for cause-specific hazards. In this model, all patients
were considered to be in a ‘‘no-GVHD’’ state on
day 0; if aGVHD occurred, they were reassigned to
the ‘‘aGVHD’’ group and remained in that group untilthe possible onset of NCC cGVHD, after which they
were moved to the ‘‘NIH cGVHD with previous
aGVHD’’ group; patients who developed cGVHD
without previous aGVHD were reassigned to ‘‘NIH
cGVHD without previous aGVHD’’ at the onset of
cGVHD.
All analyses were performed using SAS software
(SAS Institute, Cary, NC); information on the
required data format for these analyses can be found
in http://www.biomedcentral.com/content/supple-
mentary/cc6852-S1.pdf. Cumulative incidence func-
tions of the 3 GVHD subgroups were computed
with R functions from competing-risks analysis librar-
ies (R version 2.9.1; R foundation for Statistical Com-
puting, Vienna, Austria).RESULTS
Patient and Transplantation Characteristics
Table 1 presents demographic data for our pa-
tients. The median age at SCT was 36 years. The
patients had various hematologic malignancies and
underwent SCT from sibling or unrelated donors.
Unrelated donors were divided into 3 groups accord-
ing to the degree of HLA match [18]: well matched,
partially matched, and mismatched. At the time of
transplantation, 20% of the patients had advanced
disease features.
Figure 1. Cumulative incidence of GVHD by NCC. The cumulative in-
cidences of only aGVHD, classic cGVHD, and OS were 27.2%, 39.0%,
and 13.3%, respectively.
Biol Blood Marrow Transplant 18:1136-1143, 2012 1139GVT Effect of GVHD by NIH CriteriaAmong the patients who developed GVHD,
transplantation-related characteristics, including age,
donor type, graft source, intensity of conditioning
regimen, dose of CD31 cell infusion, and GVHD pro-
phylaxis, differed among the 3 GVHD subgroups
(Table 1).
Reclassification of Grade II-IV aGVHD and
cGVHD by NCC
Among the 775 patients analyzed, 524 (68%) de-
veloped aGVHD or cGVHD after SCT regardless of
onset time, and 251 (32%) did not develop GVHD.
Among the 524 patients with GVHD, 199 (38%)
developed aGVHD only, including 26 with late-
onset aGVHD; 232 (44%) developed classic cGVHD,
including 120 (52%) with de novo type and 112 (48%)
with quiescent type; and 93 (18%) developed OS,
including 58 (62%) with de novo type, 7 (8%) with
quiescent type, and 28 (30%) with progressive type.
Sixty-two of the 93 patients with OS (72%) developed
symptoms within 100 days after SCT. Of note, 52 pa-
tients (13% of all aGVHD by the NCC) who devel-
oped acute features more than 100 days after SCT
and 77 patients (24% of all cGVHD byNCC) who de-
veloped chronic features within 100 days after SCT
were reclassified as only aGVHD and classic cGVHD
by NCC. The cumulative incidence was 27.2% (95%
CI, 23.9-30.5) for the aGVHD-only group (n 5
199), 39.0% (95% CI, 35.0-42.9) for the classic
cGVHD group (n 5 232), and 13.3% (95% CI,
10.8-15.9) for the OS group (n 5 93) (Figure 1).
Potential Factors Affecting Relapse and NRM
After amedian follow-up of 41months (range, 3-90
months) in SCT survivors, the 3-year cumulativeincidence of relapse was 23.7% (95% CI, 20.5%-
26.9%), and that of NRM was 22.8% (95% CI,
19.7%-26.1%). Of the factors found to affect relapse
and NRM on univariate analyses (Table S2), advanced
disease status at transplantation was found to be signif-
icantly associated with higher relapse rate on multivar-
iate analysis. Older age, female–male donor–recipient
match, and donor type (partially matched and mis-
matched unrelated donor), as well as advanced disease
status at transplantation, were significantly associated
with higher NRM.
Multivariate analyses (Table 2) including only
aGVHD, classic cGVHD, and OS as time-dependent
covariates in addition to the foregoing time-fixed
variables revealed that classic cGVHD and OS were
associated with decreased risk of relapse. In contrast,
all 3 GVHD subtypes were associated with signifi-
cantly higherNRMcomparedwith noGVHD.Adding
time-dependent covariates of GVHD in competing-
risks models produced little change to the significance
of other independent time-fixed variables affecting re-
lapse and NRM, indicating that the time-dependent
GVHD covariates are independent predictors apart
from time-fixed variables.
Potential Factors Affecting Overall Survival and
DFS
After a median follow-up of 41 months (range, 3-
90 months) for SCT survivors, the 3-year overall sur-
vival and DFS rates were 60.7% (95% CI, 53.2-59.1)
and 54.8% (95% CI, 49.7-55.7), respectively. Of fac-
tors affecting overall survival and DFS on univariate
analyses, multivariate analyses revealed that older
age, advanced disease status at transplantation, and
more intense conditioning were significantly associ-
ated with poor outcomes, both overall survival and
DFS (Table S2). Recipients of a mismatched unrelated
donor transplantation had a lower overall survival and
DFS compared with recipients of a sibling donor
transplantation; in contrast, there was no difference
between recipients of a sibling donor transplantation
and recipients of a well-matched unrelated donor
transplantation. Receipt of a partially matched unre-
lated donor transplantation was significantly associ-
ated with lower overall survival.
Multivariate analyses including only aGVHD,
classic cGVHD, and OS as time-dependent covariates
in addition to the foregoing above time-fixed variables
revealed that only the aGVHD group was associated
with lower survival, whereas both classic cGVHD
and OS groups had no effect on survival compared
with no GVHD (Table 2). Importantly, the time-
dependent covariates of GVHD also had little effect
on the significance of other time-fixed variables affect-
ing OS and DFS, indicating that the time-dependent
GVHD covariates are independent predictors apart
from the time-fixed variables.
Table 2. Multivariate Analyses for Potential Factors Affecting Transplantation Outcomes
Variable n
Analyses with GVHD as Time-Dependent Covariate
Overall Survival DFS Relapse NRM
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Increasing age, years (continuous) 775 1.02 (1.01-1.03) <.001 1.02 (1.01-1.03) .004 1.01 (1.00-1.03) .151 1.02 (1.01-1.04) .003
Sex incompatibility - -
Female to male 169 - - 1 1
Other 606 - - 1.13 (0.76-1.69) .536 0.59 (0.41-0.84) .004
Donor type
Sibling 492 1 1 1 1
Unrelated
WM 152 0.97 (0.71-1.34) .868 0.99 (0.74-1.33) .950 0.96 (0.64-1.45) .857 1.07 (0.69-1.65) .770
PW 100 1.29 (0.92-1.79) .137 1.17 (0.85-1.62) .328 0.96 (0.59-1.55) .861 1.52 (0.98-2.36) .065
MM 31 1.56 (0.93-2.62) .089 1.62 (1.00-2.64) .051 1.57 (0.78-3.17) .204 1.75 (0.88-3.50) .111
Diagnosis
Myeloid 515 1 1 1 1
Lymphoid 260 1.20 (0.94-1.54) .146 1.06 (0.84-1.34) .630 0.91 (0.65-1.28) .575 1.29 (0.93-1.79) .134
Graft source
BM 483 1 1 1 1
PBSC 247 1.20 (0.89-1.61) .238 1.10 (0.83-1.46) .508 1.07 (0.72-1.59) .749 1.07 (0.71-1.59) .757
BM + PBSC 45 0.87 (0.50-1.50) .603 0.81 (0.48-1.38) .446 0.72 (0.34-1.51) .379 0.95 (0.45-2.01) .887
Pre-SCT disease status
Standard 622 1 1 1 1
Advanced 153 2.82 (2.18-3.64) <.001 2.38 (1.86-3.04) <.001 2.09 (1.46-2.99) <.001 2.65 (1.88-3.73) <.001
Conditioning intensity
Myeloablative conditioning 540 1 1 1 1
RIC 235 0.66 (0.48-0.92) .013 0.78 (0.57-1.05) .099 0.79 (0.52-1.19) .259 0.79 (0.50-1.22) .285
GVHD
None 251 1 1 1 1
aGVHD only 199 1.91 (1.43-2.54) <.001 1.79 (1.36-2.35) <.001 1.11 (0.76-1.63) .588 3.30 (2.18-4.98) <.001
Classic cGVHDa 232 0.86 (0.60-1.23) .395 0.96 (0.67-1.36) .799 0.46 (0.27-0.77) .003 2.40 (1.42-4.04) .001
OS 93 1.07 (0.71-1.61) .745 1.03 (0.70-1.53) .868 0.52 (0.28-0.96) .035 2.34 (1.37-3.98) .002
MM indicates mismatched; PW, partially matched; WM, well matched.
aClassic cGVHD includes 120 patients with NCC cGVHD without previous aGVHD and 112 patients with NCC cGVHD with previous aGVHD.
1140 Biol Blood Marrow Transplant 18:1136-1143, 2012B.-S. Cho et al.In addition, the separate multivariate analysis for
potential factors affecting overall survival in the cohort
excluding recipients of second allogeneic SCT and/or
DLI to remove the effect of postrelapse treatment also
found that the aGVHD-only group was associated
with lower overall survival (Table S3).Separate Multivariate Analyses to
Accommodate Changes in GVHD with Time
after SCT
Of the patients in the classic cGVHD group, 112
experienced previous aGVHD. To incorporate the ef-
fects of aGVHD occurring before the transition to
NCC cGVHD in evaluation of the overall GVT effect,
we performed separate multivariate analyses using the
Cox proportional hazards regression models for
cause-specific hazards. Table 3 summarizes the impact
of each subtype of GVHD on survival outcomes. Mul-
tivariate analyses found no association between all
events of aGVHD and the risk of relapse, whereas
NCC cGVHD with or without previous aGVHD was
associated with significantly decreased risk of relapse
compared with no GVHD. However, only patients
with cGVHD without previous aGVHD showed a
survival benefit, given that the other 2 groupswere asso-
ciated with higher NRM compared with no GVHD.DISCUSSION
In the present study, our main aim was to evaluate
whether or not newly classified NCCGVHD subtypes
are effective in reducing the incidence of relapse,
which indicates the GVT effect throughout the course
of SCT, which translates to survival outcomes. We re-
classified a group of patients diagnosed with GVHD
into acute features or chronic features of GVHD based
on NCC regardless of the time of onset into 4 groups:
no GVHD, aGVHD only, classic cGVHD, and OS.
Thirteen percent of all aGVHD cases developed
aGVHD more than 100 days after SCT, and 24% of
all cGVHD cases developed cGVHD within 100
days after SCT. This model is similar to that of
Inamoto et al. [19], in which patients were classified
in 3 exclusive conditions: grade 0-I acute GVHDwith-
out NIH chronic GVHD, grades II-IV acute GVHD
without NIH chronic GVHD, or NIH chronic
GVHD with or without acute GVHD. Clinically,
the GVT effect usually can be assessed by reducing
the probability of relapse and is seen mainly in associ-
ation with GVHD [20-22], although it can occur in the
absence of GVHD [23]. The GVT effect may also be
affected by the tumor burden at the time of transplan-
tation [24,25], disease type [26-28], stem cell source
[29-32], donor type [33], and HLA match [34,35],
Table 3. Separate Multivariate Analyses to Accommodate Changes in GVHD with Time after SCT
Variable N
Analyses with GVHD as Time-Dependent Covariates
Overall Survival DFS Relapse NRM
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Increasing age, years
(continuous)
775 1.02 (1.01-1.03) <.001 1.02 (1.01-1.03) .002 1.01 (0.99-1.03) .170 1.03 (1.01-1.04) .002
Sex incompatibility - - - -
Female to male 169 1 1
Other 606 1.10 (0.74-1.64) .642 0.61 (0.42-0.87) .006
Donor type
Sibling 492 1 1 1 1
Unrelated
WM 152 0.98 (0.73-1.37) .981 1.04 (0.77-1.40) .786 1.05 (0.70-1.58) .816 1.07 (0.69-1.66) .750
PW 100 1.36 (0.98-1.90) .070 1.31 (0.95-1.80) .106 1.08 (0.67-1.76) .745 1.61 (1.03-2.50) .035
MM 31 1.70 (1.02-2.83) .043 1.79 (1.10-2.90) .019 1.77 (0.88-3.56) .109 1.94 (0.98-3.85) .057
Diagnosis
Myeloid 515 1 1 1 1
Lymphoid 260 1.23 (0.96-1.57) .106 1.11 (0.87-1.40) .407 0.94 (0.66-1.32) .815 1.28 (0.98-1.78) .147
Graft source
BM 483 1 1 1 1
PBSC 247 1.20 (0.89-1.62) .229 1.14 (0.86-1.51) .364 1.07 (0.72-1.59) .756 1.09 (0.73-1.63) .672
BM + PBSC 45 0.89 (0.51-1.54) .669 0.85 (0.50-1.45) .555 0.76 (0.36-1.59) .462 0.94 (0.45-2.00) .880
Pre-SCT disease status
Standard 622 1 1 1 1
Advanced 153 2.70 (2.09-3.48) <.001 2.31 (1.81-2.96) <.001 2.02 (1.40-2.90) <.001 2.56 (1.82-3.59) <.001
Conditioning intensity
Myeloablative
conditioning
540 1 1 1 1
RIC 235 0.64 (0.46-0.88) .006 0.85 (0.50-1.45) .555 0.74 (0.49-1.12) .156 0.76 (0.49-1.17) .213
GVHD
None 251 1 1 1 1
aGVHD onlya 311 1.17 (0.88-1.55) .290 0.93 (0.71-1.22) .584 0.74 (0.49-1.12) .156 1.74 (1.16-2.62) .008
NCC cGVHD with
previous aGVHDb
112 1.01 (0.67-1.52) .974 0.94 (0.63-1.41) .777 0.64 (0.44-0.93) .021 3.09 (1.77-538) <.001
NCC cGVHD without
previous aGVHD
213 0.69 (0.48-0.98) .037 0.65 (0.46-0.91) .013 0.33 (0.16-0.70) .004 1.41 (0.86-2.34) .177
MM indicates mismatched; PW, partially matched; WM, well matched.
aaGVHD includes the effect of aGVHD (until just before the development of cGVHD) in patients with classic cGVHD who experienced previous
aGVHD (n 5 112), as well as patients with aGVHD only (n 5 199).
bNCC cGVHD with previous aGVHD includes only the effect of cGVHD after the development of cGVHD.
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[36,37]. Recently, Inamoto et al. [19] reported that
duration and withdrawal of immunosuppressive treat-
ment were important factors influencing the risk of
relapse. A significant GVT effect can be induced
by cGVHD rather than aGVHD [38,39]. However,
clinical studies have shown discrepant findings
regarding the relative role of aGVHD and cGVHD
and the associated GVT effects [26,27,40], possibly
reflecting a close correlation between or inappropriate
classification of aGVHD and cGVHD.
Two previous studies evaluated the GVT effect of
NCC GVHD subtype from the time of SCT. Thepot
et al. [11] reported the GVT effect of NCC cGVHD
compared with the no-GVHD group in a cohort
including only survivors after day 100 who received
RIC. Inamoto et al. [19] showed that the risk of relapse
was reduced by both NCC aGVHD and cGVHD
compared with no GVHD after SCT with high-
intensity conditioning regimens [19]. In the present
study, we evaluated the incidence and possible GVT
effect of NCC GVHD subtypes in a large cohort,including all patients throughout the course of SCT
with high-intensity conditioning and RIC. We found
that the GVT effect was largely dependent on the oc-
currence of classic cGVHD and OS. However, there
was no survival benefit in the classic cGVHD or OS
group compared with the no-GVHD group because
of higher NRM. In contrast, the aGVHD-only group
not only failed to show any GVT effect but also had
a higher NRM than the no-GVHD group, which
translated into poor survival outcomes.
Because the classic cGVHD group included 112
patients who experienced aGVHD before the occur-
rence of cGVHD, the effect of aGVHD before the
transition to cGVHDmust be incorporated for a com-
plete evaluation of the GVT effect of all forms of
aGVHD. Thus, we performed further analyses to ac-
commodate changes inGVHDtype usingCox propor-
tional hazards regression models for cause-specific
hazards. The results again failed to show any GVT
effect of aGVHD, whereas NCC cGVHD without
previous aGVHDshowed aGVTeffect as well as a sur-
vival benefit. These results are in contrast to those of
1142 Biol Blood Marrow Transplant 18:1136-1143, 2012B.-S. Cho et al.Inamoto et al. [19], which showed that GVL effects at-
tributable to aGVHD andNCC cGVHD are similarly
potent after SCTwith high-intensity conditioning reg-
imens. The differences in the conditioning intensity,
donor type, and patient characteristics may be the
possible explanations for the discrepant results, and
further, prospective studies may be needed.
Several previous retrospective studies have investi-
gated the role of theNCCGVHD subtypes in patients
surviving more than 100 days after SCT [5-11]. These
studies had limitations in evaluating differences in
clinical outcomes between aGVHD and cGVHD
because of the arbitrary exclusion of events occurring
less than 100 days after SCT and reported
conflicting results [5-11]. Studies with larger cohorts,
including the present study, found no differences
between late aGVHD and cGVHD [5,9], whereas
studies including small numbers of patients revealed
higher NRM in patients with late aGVHD compared
with patients with cGVHD [6-8,11]. In this context,
the present study, which included a large number of
patients and all GVHD events occurring before 100
days after SCT and after 100 days after SCT, is
appropriate for investigating the role of aGVHD,
classic cGVHD, or OS on clinical outcomes. Unlike
the study from Inamoto et al. [19], which grouped
GVHD in a similar manner but did not distinguish
OS from classic cGVHD, we evaluated the role of
each type of cGVHD and found no difference in clin-
ical outcomes between classic cGVHD and OS. This
result is consistent with findings from previous studies
[5,7] but conflicts with those of a study by Kim et al.
[10] showing decreased survival in patients with
NCC OS compared with those with classic cGVHD
[10]. Thus, further studies on the roles of classic
cGVHD and OS are needed.
Most importantly, the purpose of the present study
differed from that of previous studies that examined
survival and other outcomes after the onset of cGVHD
[5-10]. Instead, we focused on investigating the impact
of different subtypes of GVHD on survival outcomes
compared with patients without GVHD. For the
purpose of comparison with patients without GVHD
as the reference group, proper statistical methodology
must be applied, because GVHD is a well-known time-
dependent event. We applied time-dependent analyses
to assess the effects of aGVHD, classic cGVHD, and
OS on the risk of relapse and NRM [12,13]. Of note,
our analyses found that the significance levels of time-
fixed variables remained almost the samewith orwithout
time-dependent covariates of aGVHD, classic cGVHD,
or OS. This finding implies that NCCGVHD subtypes
are essential predictors of survival outcome and cannot
be disregarded or substantiated by other time-fixed
independent variables.
In summary, our data show that both classic
cGVHD and OS can reduce the risk of relapse,demonstrating the presence of a similarly potent
GVT effect and similar survival outcomes. Patients
with aGVHD only had poor survival outcomes due to
higher NRMwithout the GVT effect, and all aGVHD
events, including aGVHD in patients who subse-
quently developed cGVHD, had no effect on the risk
of relapse. In contrast, cGVHD without previous
aGVHD was associated with favorable survival out-
comes as well as a demonstrable GVT effect.
Although our results should be interpreted with cau-
tion given the limitations imposed by the study’s retro-
spective nature and recording bias, they show theGVT
effect of GVHD defined by theNCC in a cohort of pa-
tients with GVHD occurring within 100 days after
SCT and those with GVHD occurring more than
100 days after SCT. The distinct differences in the
GVT effects of aGVHD, classic cGVHD, and OS
suggest the usefulness of the NCC in clinical practice.
Further studies are needed to investigate risk factors,
pathogenesis, and biomarkers for each NCC GVHD
subtype. An ongoing prospective study will be con-
ducted to confirm these findings in the near future.ACKNOWLEDGMENTS
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